Related Experiment Video
Updated: Feb 1, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Alirocumab for low-density lipoprotein cholesterol lowering
1President, Sterling Research Group & Clinical Professor, Division of Cardiovascular Health & Disease, University of Cincinnati, Cincinnati, OH 45219-513, USA.
Insights
New PCSK9 inhibitors, like alirocumab, effectively lower LDL cholesterol when combined with statins. The ODYSSEY OUTCOMES trial demonstrates their efficacy and safety in reducing cardiovascular events.
Area of Science:
- Cardiovascular Medicine
- Biochemistry
- Pharmacology
Background:
- Ischemic heart disease and stroke are leading global causes of mortality.
- Atherosclerosis, driven by low-density lipoprotein cholesterol (LDL-C) deposition, underlies these conditions.
- Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates LDL-C by promoting LDL receptor degradation.
Purpose of the Study:
- To review the efficacy and safety of alirocumab, a PCSK9 inhibitor.
- To analyze the impact of alirocumab, particularly in the context of the ODYSSEY OUTCOMES trial.
Main Methods:
- Review of scientific literature and clinical trial data.
- Focus on alirocumab as a monoclonal antibody targeting PCSK9.
- Inclusion of data from the ODYSSEY OUTCOMES trial.
Main Results:
- PCSK9 inhibitors, including alirocumab, achieve significant reductions in LDL-C levels.
- Combination therapy with statins enhances LDL-C lowering.
- The ODYSSEY OUTCOMES trial provides key data on alirocumab's clinical outcomes.
Conclusions:
- Alirocumab represents a significant advancement in managing hyperlipidemia.
- PCSK9 inhibition offers a potent strategy to reduce cardiovascular risk.
- Further research and clinical application of PCSK9 inhibitors are warranted.
Abstract:
Ischemic heart disease and stroke are the leading causes of death in the world currently. Both of these conditions are primarily caused by atherosclerosis, the underlying pathophysiology of which is the deposition of lipid, specifically low-density lipoprotein cholesterol (LDL-C) within the arterial bed. PCSK9, is a proteolytic enzyme, which indirectly increases LDL-C levels by causing the destruction of LDL receptors, the main way that humans regulate their serum LDL-C levels. Inhibitors of PCSK9 in conjunction with statins have allowed achievement of very low LDL-C levels. This review will provide an in-depth efficacy and safety review of alirocumab, a monoclonal antibody inhibitor of PCSK9, including the ODYSSEY OUTCOMES trial.
Related Concept Videos
Vapor Pressure Lowering
Cholesterol: Significance and Regulation
Considering cholesterol and...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Density
Current Density
Strain-Energy Density
In the elastic region of a material, the relationship between the stress and the strain is linear and follows Hooke's Law. The strain energy density in this region...

